Private Placement

NMI launches Business Capital, an embedded lending tool giving healthcare providers fast access to funds. Is this the lifeline the industry needs?

A modest SEK 1.5 million order may not turn heads, but for Cell Impact, it's a critical validation that could unlock mass production in the booming Asian FCEV market.

A new narcolepsy drug could finally offer patients what they've been missing: a single nightly dose with low sodium, transforming lives and the market.

After a financial tightrope walk, Actelis Networks is back in Nasdaq's good graces. But the real story is its mission to secure our future's IoT.

JFB Construction's CEO just invested $100k of his own money in company stock. We dive into the projects and market trends fueling this bold move.

Once mired in debt, Castellum has secured over $170M in prime contracts, signaling a dramatic resurgence in the competitive federal defense market.

A quiet investment in a communication platform is making a loud statement about the future of work and education. Here’s why it matters for your brand.

With stellar clinical data for its TERN-701 drug, Terns is raising massive capital to challenge Novartis and reshape the multi-billion-dollar CML market.

For those with severe PTSD and depression, hope is scarce. Biotech firm Compass Pathways is pioneering a psilocybin treatment that could change everything.

With backing from the US and Australia, a titanium giant is pivoting to critical minerals, a strategic move challenging global supply chain dominance.

The platform's 2025 report reveals more than just charity; it's a real-time indicator of economic distress, disaster response, and tech-driven mutual aid.

Advanced chip packaging is the unsung hero of the AI revolution, with a market set to explode. But can the industry sustain its billion-dollar habit?

A deep dive into 22 Fulton Street, where complex finance, green design, and affordable housing converge to reshape Newark's skyline and its community.

FDA clears Phase IIb trial for CS1, an epigenetic drug aiming to reverse PAH damage, not just manage symptoms, signaling a major market and patient shift.

A Japanese EdTech firm is offering unlimited free English lessons in Brazil. Is this a savvy market capture or a high-risk gamble in a crowded space?

An innovative partnership in Quebec is building debt-free, affordable homes for seniors, offering a replicable model to tackle the national housing crisis.

A Houston biotech reports a 100% response rate with its new CAR-T therapy, offering a potential lifeline for patients with a devastatingly rare cancer.

A sleepy cat GIF with 2.4B views is now a children's book. We analyze the business strategy behind turning viral fame into a publishing success story.

John Crowley, who fought to save his own children, will now shape the future of medicine as he headlines the landmark 2026 MDA conference.

Fate Therapeutics' latest data suggests its iPSC-derived CAR-T could revolutionize lupus care, moving cell therapy beyond cancer and into the mainstream.